Philip Morris International Inc (PM)

The Transformation Story: From Cigarettes to Smoke-Free

Philip Morris International (PM) is routinely mislabeled as 'just a cigarette company.' That description is outdated. Over the past several years, PMI has been executing one of the more unusual business transformations in the consumer staples sector — pivoting away from its traditional combustible-cigarette model toward smoke-free nicotine products, led by IQOS (heated tobacco), ZYN (nicotine pouches), and VEEV (e-vapor).

The numbers make the direction unmistakable. In FY2025, total smoke-free shipment volume grew +12.8% year-over-year to 179.1 billion units, while traditional cigarette shipments declined -1.5% to 607.4 billion units. That cigarette decline isn't a surprise — it reflects a well-known, industry-wide structural trend — but the key point is that PMI has now built a growth engine large enough to more than offset it.

Segment Breakdown

FY2025 net revenue reached $40.6 billion, up +7.3% YoY — driven almost entirely by smoke-free momentum. PMI's medium-term target is for smoke-free products to exceed 50% of total net revenue.

Leadership and Corporate History

PMI is led by CEO Jacek Olczak, who took the role in 2021 after a long tenure within the organization, including as Chief Financial Officer. PMI itself has existed as a separately-listed entity since 2008, when it was spun off from Altria Group — a split that separated the international tobacco business (PMI) from the U.S. business (Altria/Marlboro).

Several major corporate actions have shaped PMI as it stands today:

• Swedish Match acquisition (2022, ~$17.6B) — brought the ZYN nicotine pouch brand into PMI's portfolio, now one of the company's fastest-growing product lines.
• 'Beyond Nicotine' pivot (Vectura, Fertin Pharma) — PMI's push into inhaled drug delivery and health-adjacent products, entirely outside nicotine. This is a more speculative, longer-horizon bet compared to the core nicotine business.
• IQOS US re-entry — after a patent dispute with British American Tobacco forced IQOS off US shelves from 2021-2024, PMI regained full US commercialization rights in April 2024 and began a direct-to-consumer relaunch in Austin, Texas in March 2025.

Shariah Compliance Status

❌ NON-COMPLIANT — PMI manufactures tobacco and nicotine products. This is a hard-fail under Shariah screening — regardless of how favorable the company's financial ratios might be, the core business activity (manufacturing and selling tobacco/nicotine products) is enough to exclude this stock from any Shariah-compliant list. This report is for educational and analytical purposes only and is explicitly not a Shariah-compliant recommendation.

This section is being refreshed with the latest figures. Please check back soon.

This section is being refreshed with the latest figures. Please check back soon.